However, Willow opted to defend its advertising claims against a challenge from Novo Nordisk, prompting NAD review of their substantiation and truthfulness
The Global Obesity Crisis Nearly 900 million adults around the world are living with obesity
After the second or third year, discontinuation rates often decline
Lower Risk Across All Key Outcomes with GLP-1RA Compared with DPP-4 inhibitors, GLP-1RA use was associated with significantly lower risks of MACE (hazard ratio [HR]: 0.66), VTE (HR: 0.49), kidney disease progression (HR: 0.77), and all-cause mortality (HR: 0.26)
Start small, make gradual adjustments, and dont hesitate to reach out to your doctor for extra guidance
In addition, if you use semaglutide, tirzepatide, or orforglipron, that doesnt mean you can forget about following a healthy lifestyle